BIOA
$10.60
+$0.17 (1.63%)+1.63%
After HoursLoading chart...
IndexN/A
Market Cap0.40B
Enterprise Value0.29B
Income$-0.01B
Sales$0.00B
EmployeesN/A
P/E-4.45
P/S52.85
P/B1.75
P/C-5.77
EV/EBITDA-3.66
EV/SalesN/A
EPS (ttm)-2.38
EarningsN/A
Gross Margin100.00%
Oper. Margin-1031.46%
Profit Margin-896.11%
Volume0.44M
Shs Outstand0.04B
Change1.63%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Gross Margin | N/A | N/A | N/A |
| Operating Expenses | $78.19M | $48.40M | $39.97M |
| Operating Income | $-78.19M | $-48.40M | $-39.97M |
| Operating Margin | N/A | N/A | N/A |
| Net Income | $-71.11M | $-63.85M | $-39.72M |
| Net Margin | N/A | N/A | N/A |
| EPS (Basic) | $-6.63 | $-8.55 | $-5.32 |
| EBITDA | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A |
| Total Assets | $358.23M | $25.92M | $28.43M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A |
| Total Liabilities | $35.11M | $199.32M | $140.99M |
| Non-Equity Reserves | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A |
| Total Shareholders Equity | $323.13M | $-173.40M | $-112.56M |
| Accumulated Minority Interest | N/A | N/A | N/A |
| Total Equity | $323.13M | $-173.40M | $-112.56M |
| Total Liabilities & Stockholders Equity | $358.23M | $25.92M | $28.43M |
| Book Value Per Share | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Net Income | $-71.11M | $-63.85M | $-39.72M |
| Depreciation | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A |
| Cash from Operating Activities | $-51.52M | $-37.36M | $-36.18M |
| Capital Expenditures | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A |
Company coverage
Latest news
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire Inc. BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular RiskGlobeNewswire Inc. BioAge Labs to Present at Upcoming Investor ConferencesGlobeNewswire Inc. Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsBenzinga BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRPGlobeNewswire Inc. BioAge Announces Pricing of Upsized $115.0 Million Public OfferingGlobeNewswire Inc. BioAge Announces Proposed Public OfferingBenzinga BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026GlobeNewswire Inc.
Show 12 more stories
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot PoleThe Motley Fool Top 3 Biotech Stocks Capitalizing on the AI RevolutionInvesting.com BioAge Labs to Present at Jefferies Global Healthcare Conference in LondonGlobeNewswire Inc. BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?The Motley Fool BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 InhibitorGlobeNewswire Inc. BioAge Labs (BIOA) Q2 Revenue Hits $2.4MThe Motley Fool BIOA LEGAL NEWS: A Class Action was filed on behalf of BioAge Labs Investors - Contact BFA Law if You Suffered LossesGlobeNewswire Inc. Deadline Alert: BioAge Labs, Inc. (BIOA) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitGlobeNewswire Inc. BIOA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitGlobeNewswire Inc. BIOA DEADLINE ALERT: BioAge Labs (BIOA) Investors with Losses Encouraged to Contact Hagens Berman Before Mar. 10th Deadline in Securities Class ActionGlobeNewswire Inc. BIOA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that BioAge Labs, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action LawsuitGlobeNewswire Inc. BIOA Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against BioAge Labs, Inc. (BIOA)GlobeNewswire Inc.
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Discover more
You may be interested in